OrganOx Ltd, a leading medical technology company specialising in organ preservation prior to transplantation and the treatment of acute organ failure, has opened its new 18,000 square-foot global headquarters for research, development, and production in Oxford.
Founded in 2008 as a spin-out from the University of Oxford and supported by the team at Oxford University Innovation, OrganOx developed the world’s first normothermic liver perfusion device, the metra®.
This device preserves donor livers at body temperature by circulating oxygenated blood and nutrients through them. Launched in Europe in 2018 and the U.S. in 2022, the metra® has quickly gained market adoption, increasing organ transplants, eliminating night-time surgeries, and improving patient outcomes.
Craig Marshall, CEO of OrganOx, said: “Our new facility opening is a major milestone, providing OrganOx stakeholders access to world-class facilities and technologies as we work together in ways that were simply not possible previously. We are proud to be a growing member of the Oxford business and scientific community, and I am greatly looking forward to broader collaborations with commercial and clinical partners.”
Prof. Peter Friend, FMedSci, Chief Medical Officer, and Co-Founder of OrganOx, added: “We are all excited about what the future holds for OrganOx as we continue to push the scientific and clinical boundaries with technology-based solutions designed to improve the lives of patients experiencing acute or chronic organ failure. This remarkable new facility will support us in that mission for many years to come.”
Prof. Constantin Coussios – the other cofounder of OrganOx, has just been elected as a Fellow of the Academy of Medical Sciences.